Medicalization, Direct-to-Consumer Advertising, and Mental Illness Stigma

Society and Mental Health

Volumn 1, Issue 1, 2011, Pages 55-70

  Payton, Andrew R ^a   Thoits, Peggy A ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

depression; social control; stigma

Indexed keywords

EID: 84993731446     PISSN: 21568693     EISSN: 21568731     Source Type: Journal    
DOI: 10.1177/2156869310397959     Document Type: Article

References (47)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association.
2. Arnold M. 2006. “The Science of DTC.” Medical Marketing and Media 41:38–45.
3. Brown Phil. 1995. “Naming and Framing: The Social Construction of Diagnosis and Illness.” Journal of Health and Social Behavior 35(extra issue):34–52.
4. Brownfield Erica D. Bernhardt Jay M. Phan Jennifer L. Williams Mark V. Parker Ruth M. 2004. “Direct-to-Consumer Drug Advertisements on Network Television: An Exploration of Quantity, Frequency, and Placement.” Journal of Health Communication 9:491–97.
5. Clarke Adele E. Shim Janet K. Mamo Laura Fosket Jennifer Ruth Fishman Jennifer R. 2003. “Biomedicalization: Technoscientific Transformations of Health, Illness, and US Biomedicine.” American Sociological Review 68:161–94.
6. Conrad Peter. 1992. “Medicalization and Social Control.” Annual Review of Sociology 18:209–32.
7. Conrad Peter. 2005. “The Shifting Engines of Medicalization.” Journal of Health and Social Behavior 46:3–14.
8. Conrad Peter. 2007. The Medicalization of Society. Baltimore: Johns Hopkins University Press.
9. Conrad Peter Leiter Valerie. 2004. “Medicalization, Markets and Consumers.” Journal of Health and Social Behavior 45:158–76.
10. Conrad Peter Leiter Valerie. 2008. “From Lydia Pinkham to Queen Levitra: Direct-to-Consumer Advertising and Medicalisation.” Sociology of Health and Illness 30:825–38.
11. Conrad Peter Schneider Joseph W. 1992. Deviance and Medicalization: From Badness to Sickness. Philadelphia: Temple University Press.
12. Davis J.A. Smith T. W. Marsden P. V. 2007. General Social Surveys, 1972-2006: Cumulative Codebook. Chicago: National Opinion Research Center.
13. Donohue Julie M. Cevasco M. Rosenthal M. B. 2007. “A Decade of Direct-to-Consumer Advertising of Prescription Drugs.” New England Journal of Medicine 357:673–81.
14. Frank Arthur W. 1995. The Wounded Storyteller. Chicago: University of Chicago Press.
15. Freidson Elliot. 1970. Profession of Medicine: A Study of the Sociology of Applied Knowledge. Chicago: University of Chicago Press.
16. Gellad Ziad F. Lyles Kenneth W. 2007. “Direct-to-Consumer Advertising of Pharmaceuticals.” American Journal of Medicine 120:475–80.
17. Goffman Erving. 1963. Stigma: Notes on the Management of a Spoiled Identity. Englewood Cliffs, NJ: Prentice Hall.
18. Hinshaw Stephen P. 2007. The Mark of Shame: Stigma of Mental Illness and an Agenda for Change. New York: Oxford University Press.
19. Hollon M. F. 2005. “Direct-to-Consumer Advertising: A Haphazard Approach to Health Promotion.” Journal of the American Medical Association 293:2030–33.
20. Illich Ivan. 1976. Medical Nemesis: The Expropriation of Health. New York: Pantheon Books.
21. Koerner Brendan I. 2002. “Disorders, Made to Order.” Mother Jones 27:58–63.
22. Kravitz Richard L. Epstein Ronald M. Feldman Mitchell D. Franz Carol E. Azari Rahman Wilkes Michael S. Hinton Ladson Franks Peter. 2005. “Influence of Patients’ Requests for Direct-to-Consumer Advertised Antidepressants.” Journal of the American Medical Association 293:1995–2002.
23. Link Bruce G. Phelan C. 2001. “Conceptualizing Stigma.” Annual Review of Sociology 27:363–85.
24. Link Bruce G. Phelan Jo C. Bresnahan Michaeline Stueve Ann Pescosolido Bernice A. 1999. “Public Conceptions of Mental Illness: Labels, Causes, Dangerousness, and Social Distance.” American Journal of Public Health 89:1328–33.
25. Lipsky Martin S. Taylor Christine A. 1997. “The Opinions and Experiences of Family Physicians Regarding Direct-to-Consumer Advertising.” Journal of Family Practice 45:295–300.
26. Lyles Alan. 2002. “Direct Marketing of Pharmaceuticals to Consumers.” Annual Review of Public Health 23:73–91.
27. Major Brenda Eccleston Collette P. 2005. “Stigma and Social Exclusion.” Pp. 63–87 in The Social Psychology of Inclusion and Exclusion, edited by Ed. Abrams D. Hogg M. A. Marques J. M. New York: Psychology Press.
28. Manhattan Research. 2005. “DTC Drug Ads Promote Learning for 89.4M Consumers.” November 29. Retrieved January 10, 2009 ( http://www.manhattanresearch.com/newsroom/Press_Releases/11292005.aspx ).
29. Manhattan Research. 2006. “Manhattan Research Reveals Top Ten Consumer-Ranked Pharmaceutical Product Websites. March 7. Retrieved January 10, 2009 ( http://www.manhattanresearch.com/newsroom/Press_Releases/03072006_-_ePC.aspx ).
30. Manhattan Research. 2007. “Manhattan Research Reveals Top Consumer-Ranked Pharmaceutical Product Websites. March 6. Retrieved January 10, 2009 ( http://www.manhattanresearch.com/files/PRESS/ePharma_Consumer_030607.pdf ).
31. Mintzes Barbara Barer Morris L. Kavitz Richard L. Bassett Ken Lexchin Joel Kazanjian Armine Evans Robert G. Pan Richard Marion Stephen A. 2003. “How Does Direct-to-Consumer Advertising (DTCA) Affect Prescribing? A Survey in Primary Care Environments with and without Legal DTCA.” Canadian Medical Association Journal 169:405–12.
32. Mojtabai Ramin. 2007. “Americans’ Attitudes Toward Mental Health Treatment-Seeking: 1990-2003.” Psychiatric Services 56:642–51.
33. Moynihan Ray Heath Iona Henry David. 2002. “Selling Sickness: The Pharmaceutical Industry and Disease Mongering.” British Medical Journal 324:886–90.
34. Pescosolido Bernice A. Martin Jack K. Long J. Scott Medina Tait R. Phelan J.O. Link Bruce G. 2010. “‘A Disease Like Any Other’? A Decade of Change in Public Reactions to Schizophrenia, Depression and Alcohol Dependence.” American Journal of Psychiatry 167:1321–30.
35. Pescosolido Bernice A. Monahan John Link Bruce G. Stueve Ann Kikuzawa Saeko. 1999. “The Public's View of the Competence, Dangerousness, and Need for Legal Coercion of Persons with Mental Health Problems.” American Journal of Public Health 89:1339–45.
36. Phelan C. 2005. “Geneticization of Deviant Behavior and Consequences for Stigma: The Case of Mental Illness.” Journal of Health and Social Behavior 46:307–22.
37. Relmen Arnold S. Angell Marcia. 2002. “America's Other Drug Problem.” New Republic, December 16, pp. 27–41.
38. Riessman Catherine Kohler. 1983. “Women and Medicalization: A New Perspective.” Social Policy 14:3–18.
39. Rosenthal M. B. Berndt E. R. Donohue J. M. Frank R. G. Epstein A. M. 2002. “Promotion of Prescription Drugs to Consumers.” New England Journal of Medicine 346:498–505.
40. Singer Natasha. 2009. “Citing Risks, Lawmakers Seek to Curb Prescription Drug Commercials.” New York Times, July 27, pp. B1, B6.
41. Smardon Regina. 2008. “‘I'd Rather Not Take Prozac’: Stigma and Commodification in Antidepressant Consumer Narratives.” Health 12:67–86.
42. Stout Patricia A. Villegas Jorge Jennings Nancy A. 2004. “Images of Mental Illness in the Media: Identifying Gaps in the Research.” Schizophrenia Bulletin 30:543–61.
43. Szasz Thomas S. 1960. “The Myth of Mental Illness.” American Psychologist 15:113–18.
44. Wahl Otto F. 1997. Media Madness: Public Images of Mental Illness. Piscataway, NJ: Rutgers University Press.
45. Wilkes Michael S. Bell Robert A. Kravitz Richard L. 2000. “Direct-to-Consumer Prescription Drug Advertising: Trends, Impacts, and Implications.” Health Affairs 19:110–28.
46. Williams Simon J. Gabe Jonathan Davis Peter. 2008. “The Sociology of Pharmaceuticals: Progress and Prospects.” Sociology of Health and Illness 30:813–24.
47. Williams Simon J. Seale Clive Boden Sharon Lowe Pam Steinberg Deborah Lynn. 2008. “Waking Up to Sleepiness: Modafinil, the Media and the Pharmaceuticalisation of Everyday/night Life.” Sociology of Health and Illness 30:839–55.